Ezb Myc Diffuse Large B Cell Lymphoma Cn377570
Ezb Myc Diffuse Large B-Cell Lymphoma is a highly aggressive form of non-Hodgkin lymphoma with MYC gene changes. It requires intensive chemotherapy and carries a poorer outlook than standard DLBCL.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Rapidly enlarging lymph nodes
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
B symptoms
(oncologic)Fatigue
(oncologic)Elevated LDH
(oncologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Rituximab-based chemotherapy regimen
First-line immunochemotherapy combining rituximab with anthracycline-based chemotherapy for CD20-positive diffuse large B-cell lymphoma. This targeted approach addresses the aggressive nature of MYC-rearranged lymphomas.
Additional treatment options
Autologous stem cell transplantation
High-dose chemotherapy followed by rescue with harvested stem cells, considered for patients who achieve response but are at high risk for relapse.
procedureSalvage chemotherapy
Alternative chemotherapy regimens for patients who do not respond to initial treatment or experience disease relapse.
medicationRadiation therapy
Involves targeted radiation to areas of bulky disease or residual lymphoma, often used as consolidation or for local disease control.
procedureResponse assessment and surveillance
Regular imaging studies and laboratory tests to monitor treatment response, detect relapse early, and assess for treatment-related complications.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Ezb Myc Diffuse Large B Cell Lymphoma Cn377570?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Ezb Myc Diffuse Large B Cell Lymphoma Cn377570. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy